The PTAP sequence within the p6 domain of human immunodeficiency virus type 1 gag regulates its ubiquitination and MHC class I antigen presentation

Journal of Immunology

Volumn 186, Issue 10, 2011, Pages 5706-5718

  Hahn, Sabine ^a   Setz, Christian ^a   Wild, Julia ^a   Schubert, Ulrich ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEFECTIVE RIBOSOMAL PRODUCT; EPITOPE; GAG PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN MOTIF; UBIQUITINATION; VIRUS LIKE AGENT; VIRUS RELEASE;

AMINO ACID MOTIFS; ANTIGEN PRESENTATION; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RIBOSOMES; RNA, SMALL INTERFERING; UBIQUITINATION;

EID: 79956220378     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003764     Document Type: Article

References (100)

1. Pickart, C. M., and D. Fushman. 2004. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. 8: 610-616.
2. Chen, Z. J., and L. J. Sun. 2009. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33: 275-286.
3. Thrower, J. S., L. Hoffman, M. Rechsteiner, and C. M. Pickart. 2000. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19: 94-102.
4. Goldberg, A. L., and K. L. Rock. 1992. Proteolysis, proteasomes and antigen presentation. Nature 357: 375-379.
5. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16: 323-358.
6. Shastri, N., S. Cardinaud, S. R. Schwab, T. Serwold, and J. Kunisawa. 2005. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol. Rev. 207: 31-41.
7. Yewdell, J. W., L. C. Antón, and J. R. Bennink. 1996. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157: 1823-1826.
8. Schubert, U., L. C. Antón, J. Gibbs, C. C. Norbury, J. W. Yewdell, and J. R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
9. Yewdell, J. W. 2007. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19: 79-86.
10. Cardinaud, S., S. R. Starck, P. Chandra, and N. Shastri. 2010. The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS ONE 5: e8692.
11. Dolan, B. P., L. Li, K. Takeda, J. R. Bennink, and J. W. Yewdell. 2010. Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase. J. Immunol. 184: 1419-1424.
12. Qian, S. B., E. Reits, J. Neefjes, J. M. Deslich, J. R. Bennink, and J. W. Yewdell. 2006. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 177: 227-233.
13. Qian, S. B., M. F. Princiotta, J. R. Bennink, and J. W. Yewdell. 2006. Characterization of rapidly degraded polypeptides in mammalian cells reveals a novel layer of nascent protein quality control. J. Biol. Chem. 281: 392-400.
14. Goldwich, A., S. S. Hahn, S. Schreiber, S. Meier, E. Kämpgen, R. Wagner, M. B. Lutz, and U. Schubert. 2008. Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation. J. Immunol. 180: 372-382.
15. Bryant, M., and L. Ratner. 1990. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA 87: 523-527.
16. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral Gag proteins. AIDS 5: 639-654.
17. Bieniasz, P. D. 2009. The cell biology of HIV-1 virion genesis. Cell Host Microbe 5: 550-558.
18. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Côté, R. L. Rich, et al. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107: 55-65. (Pubitemid 32972037)
19. Göttlinger, H. G., T. Dorfman, J. G. Sodroski, and W. A. Haseltine. 1991. Effect of mutations affecting the p6 Gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. USA 88: 3195-3199.
20. Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69: 6810-6818.
21. Strack, B., A. Calistri, S. Craig, E. Popova, and H. G. Göttlinger. 2003. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114: 689-699.
22. Putterman, D., R. B. Pepinsky, and V. M. Vogt. 1990. Ubiquitin in avian leukosis virus particles. Virology 176: 633-637.
23. Martin-Serrano, J. 2007. The role of ubiquitin in retroviral egress. Traffic 8: 1297-1303. (Pubitemid 47394235)
24. Vogt, V. M. 2000. Ubiquitin in retrovirus assembly: actor or bystander? Proc. Natl. Acad. Sci. USA 97: 12945-12947.
25. Ott, D. E., L. V. Coren, T. D. Copeland, B. P. Kane, D. G. Johnson, R. C. Sowder, II, Y. Yoshinaka, S. Oroszlan, L. O. Arthur, and L. E. Henderson. 1998. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus. J. Virol. 72: 2962-2968.
26. Gurer, C., L. Berthoux, and J. Luban. 2005. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J. Virol. 79: 910-917. (Pubitemid 40053874)
27. Ott, D. E., L. V. Coren, E. N. Chertova, T. D. Gagliardi, and U. Schubert. 2000. Ubiquitination of HIV-1 and MuLV Gag. Virology 278: 111-121. (Pubitemid 32002600)
28. Gottwein, E., and H. G. Kräusslich. 2005. Analysis of human immunodeficiency virus type 1 Gag ubiquitination. J. Virol. 79: 9134-9144.
29. Gottwein, E., S. Jäger, A. Habermann, and H. G. Kräusslich. 2006. Cumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 Gag cause a late budding defect. J. Virol. 80: 6267-6275.
30. Strack, B., A. Calistri, M. A. Accola, G. Palu, and H. G. Gottlinger. 2000. A role for ubiquitin ligase recruitment in retrovirus release. Proc. Natl. Acad. Sci. USA 97: 13063-13068.
31. Martin-Serrano, J., D. Perez-Caballero, and P. D. Bieniasz. 2004. Context-dependent effects of L domains and ubiquitination on viral budding. J. Virol. 78: 5554-5563.
32. Jäger, S., E. Gottwein, and H. G. Kräusslich. 2007. Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association. J. Virol. 81: 9193-9201.
33. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59: 284-291.
34. Schindler, M., J. Münch, and F. Kirchhoff. 2005. Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanism. J. Virol. 79: 5489-5498. (Pubitemid 40548217)
35. Clavel, F., M. D. Hoggan, R. L. Willey, K. Strebel, M. A. Martin, and R. Repaske. 1989. Genetic recombination of human immunodeficiency virus. J. Virol. 63: 1455-1459. (Pubitemid 19061393)
36. Votteler, J., E. Iavnilovitch, O. Fingrut, V. Shemesh, D. Taglicht, O. Erez, S. Sörgel, T. Walther, N. Bannert, U. Schubert, and Y. Reiss. 2009. Exploring the functional interaction between POSH and ALIX and the relevance to HIV-1 release. BMC Biochem. 10: 12.
37. Fossen, T., V. Wray, K. Bruns, J. Rachmat, P. Henklein, U. Tessmer, A. Maczurek, P. Klinger, and U. Schubert. 2005. Solution structure of the human immunodeficiency virus type 1 p6 protein. J. Biol. Chem. 280: 42515-42527.
38. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
39. Köhler, G., K. Fisher-Lindahl, and C. Heusser. 1981. Characterization of a monoclonal anti-H-2Kd antibody. C. M. Steinberg, and I. Lefkovits, eds. In The Immune System, Vol. 2. Karger, Basel, p. 202-208.
40. Sanderson, S., and N. Shastri. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6: 369-376.
41. Willey, R. L., D. H. Smith, L. A. Lasky, T. S. Theodore, P. L. Earl, B. Moss, D. J. Capon, and M. A. Martin. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62: 139-147.
42. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46: 1896-1905.
43. Graf, M., A. Bojak, L. Deml, K. Bieler, H. Wolf, and R. Wagner. 2000. Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74: 10822-10826.
44. Ott, D. E., L. V. Coren, R. C. Sowder, II, J. Adams, and U. Schubert. 2003. Retroviruses have differing requirements for proteasome function in the budding process. J. Virol. 77: 3384-3393. (Pubitemid 36297257)
45. Hoyt, M. A., and P. Coffino. 2004. Ubiquitin-free routes into the proteasome. Cell. Mol. Life Sci. 61: 1596-1600.
46. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67: 425-479.
47. Tao, M., P. C. Scacheri, J. M. Marinis, E. W. Harhaj, L. E. Matesic, and D. W. Abbott. 2009. ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways. Curr. Biol. 19: 1255-1263.
48. Finley, D., S. Sadis, B. P. Monia, P. Boucher, D. J. Ecker, S. T. Crooke, and V. Chau. 1994. Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Mol. Cell. Biol. 14: 5501-5509.
49. York, I. A., S. C. Chang, T. Saric, J. A. Keys, J. M. Favreau, A. L. Goldberg, and K. L. Rock. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 3: 1177-1184.
50. Wherry, E. J., K. A. Puorro, A. Porgador, and L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163: 3735-3745.
51. Zhou, W., L. J. Parent, J. W. Wills, and M. D. Resh. 1994. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J. Virol. 68: 2556-2569.
52. VerPlank, L., F. Bouamr, T. J. LaGrassa, B. Agresta, A. Kikonyogo, J. Leis, and C. A. Carter. 2001. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad. Sci. USA 98: 7724-7729.
53. Martin-Serrano, J., T. Zang, and P. D. Bieniasz. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7: 1313-1319.
54. Amit, I., L. Yakir, M. Katz, Y. Zwang, M. D. Marmor, A. Citri, K. Shtiegman, I. Alroy, S. Tuvia, Y. Reiss, et al. 2004. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev. 18: 1737-1752. (Pubitemid 38938189)
55. Usami, Y., S. Popov, and H. G. Göttlinger. 2007. Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site. J. Virol. 81: 6614-6622.
56. Fisher, R. D., H. Y. Chung, Q. Zhai, H. Robinson, W. I. Sundquist, and C. P. Hill. 2007. Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 128: 841-852.
57. Dussupt, V., M. P. Javid, G. Abou-Jaoudé, J. A. Jadwin, J. de La Cruz, K. Nagashima, and F. Bouamr. 2009. The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding. PLoS Pathog. 5: e1000339.
58. Munshi, U. M., J. Kim, K. Nagashima, J. H. Hurley, and E. O. Freed. 2007. An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J. Biol. Chem. 282: 3847-3855.
59. Komander, D. 2009. The emerging complexity of protein ubiquitination. Biochem. Soc. Trans. 37: 937-953.
60. Qian, S. B., J. R. Bennink, and J. W. Yewdell. 2005. Quantitating defective ribosome products. Methods Mol. Biol. 301: 271-281.
61. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
62. Seifert, U., L. P. Bialy, F. Ebstein, D. Bech-Otschir, A. Voigt, F. Schrö ter, T. Prozorovski, N. Lange, J. Steffen, M. Rieger, et al. 2010. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142: 613-624.
63. Van den Eynde, B. J., and S. Morel. 2001. Differential processing of class-Irestricted epitopes by the standard proteasome and the immunoproteasome. Curr. Opin. Immunol. 13: 147-153.
64. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
65. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al; Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893.
66. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5: 233-236.
67. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
68. Letvin, N. L. 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56: 213-223.
69. + T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76: 2298-2305.
70. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13: 46-53.
71. Rolland, M., D. Heckerman, W. Deng, C. M. Rousseau, H. Coovadia, K. Bishop, P. J. Goulder, B. D. Walker, C. Brander, and J. I. Mullins. 2008. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 3: e1424.
72. Martins, M. A., N. A. Wilson, J. S. Reed, C. D. Ahn, Y. C. Klimentidis, D. B. Allison, and D. I. Watkins. 2010. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J. Virol. 84: 4352-4365.
73. Grant, E. P., M. T. Michalek, A. L. Goldberg, and K. L. Rock. 1995. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 155: 3750-3758.
74. Princiotta, M. F., D. Finzi, S. B. Qian, J. Gibbs, S. Schuchmann, F. Buttgereit, J. R. Bennink, and J. W. Yewdell. 2003. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18: 343-354.
75. Sijts, A., D. Zaiss, and P. M. Kloetzel. 2001. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr. Mol. Med. 1: 665-676.
76. Tobery, T., and R. F. Siliciano. 1999. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J. Immunol. 162: 639-642.
77. Townsend, A., J. Bastin, K. Gould, G. Brownlee, M. Andrew, B. Coupar, D. Boyle, S. Chan, and G. Smith. 1988. Defective presentation to class Irestricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168: 1211-1224.
78. Wong, S. B., C. B. Buck, X. Shen, and R. F. Siliciano. 2004. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J. Immunol. 173: 3073-3083.
79. Leachman, S. A., M. Shylankevich, M. D. Slade, D. Levine, R. K. Sundaram, W. Xiao, M. Bryan, D. Zelterman, R. E. Tiegelaar, and J. L. Brandsma. 2002. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J. Virol. 76: 7616-7624.
80. Starodubova, E., A. Boberg, E. V. Kashuba, B. Wahren, V. Karpov, and M. Isaguliants. 2006. HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. Vaccine 24: 4541-4547. (Pubitemid 43776778)
81. Tellam, J., G. Connolly, N. Webb, J. Duraiswamy, and R. Khanna. 2003. Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity. Blood 102: 4535-4540. (Pubitemid 37494121)
82. Wu, Y., and T. J. Kipps. 1997. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159: 6037-6043.
83. Rodriguez, F., J. Zhang, and J. L. Whitton. 1997. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71: 8497-8503.
84. Xiang, R., H. N. Lode, T. H. Chao, J. M. Ruehlmann, C. S. Dolman, F. Rodriguez, J. L. Whitton, W. W. Overwijk, N. P. Restifo, and R. A. Reisfeld. 2000. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. USA 97: 5492-5497.
85. Huebener, N., S. Fest, A. Strandsby, E. Michalsky, R. Preissner, Y. Zeng, G. Gaedicke, and H. N. Lode. 2008. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol. Cancer Ther. 7: 2241-2251.
86. Khan, S., R. de Giuli, G. Schmidtke, M. Bruns, M. Buchmeier, M. van den Broek, and M. Groettrup. 2001. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167: 4801-4804. (Pubitemid 33009706)
87. Reits, E. A., J. C. Vos, M. Grommé, and J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404: 774-778. (Pubitemid 30212406)
88. Ravid, T., and M. Hochstrasser. 2008. Diversity of degradation signals in the ubiquitin-proteasome system. Nat. Rev. Mol. Cell Biol. 9: 679-690.
89. Dantuma, N. P., S. Heessen, K. Lindsten, M. Jellne, and M. G. Masucci. 2000. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc. Natl. Acad. Sci. USA 97: 8381-8385.
90. Mulder, L. C., and M. A. Muesing. 2000. Degradation of HIV-1 integrase by the N-end rule pathway. J. Biol. Chem. 275: 29749-29753.
91. Schubert, U., D. E. Ott, E. N. Chertova, R. Welker, U. Tessmer, M. F. Princiotta, J. R. Bennink, H. G. Krausslich, and J. W. Yewdell. 2000. Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 97: 13057-13062.
92. Müller, B., M. Anders, H. Akiyama, S. Welsch, B. Glass, K. Nikovics, F. Clavel, H. M. Tervo, O. T. Keppler, and H. G. Kräusslich. 2009. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284: 29692-29703.
93. Saeki, Y., T. Kudo, T. Sone, Y. Kikuchi, H. Yokosawa, A. Toh-e, and K. Tanaka. 2009. Lysine 63-linked polyubiquitin chain may serve as a targeting signal for the 26S proteasome. EMBO J. 28: 359-371.
94. Bieniasz, P. D. 2006. Late budding domains and host proteins in enveloped virus release. Virology 344: 55-63. (Pubitemid 41814450)
95. Agromayor, M., and J. Martin-Serrano. 2006. Interaction of AMSH with ESCRT-III and deubiquitination of endosomal cargo. J. Biol. Chem. 281: 23083-23091.
96. Myers, E. L., and J. F. Allen. 2002. Tsg101, an inactive homologue of ubiquitin ligase E2, interacts specifically with human immunodeficiency virus type 2 Gag polyprotein and results in increased levels of ubiquitinated Gag. J. Virol. 76: 11226-11235.
97. Minami, R., A. Hayakawa, H. Kagawa, Y. Yanagi, H. Yokosawa, and H. Kawahara. 2010. BAG-6 is essential for selective elimination of defective proteasomal substrates. J. Cell Biol. 190: 637-650.
98. Bansal, A., J. Carlson, J. Yan, O. T. Akinsiku, M. Schaefer, S. Sabbaj, A. Bet, D. N. Levy, S. Heath, J. Tang, et al. 2010. CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J. Exp. Med. 207: 51-59.
99. Casartelli, N., F. Guivel-Benhassine, R. Bouziat, S. Brandler, O. Schwartz, and A. Moris. 2010. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 207: 39-49.
100. Bullock, T. N., D. W. Mullins, and V. H. Engelhard. 2003. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J. Immunol. 170: 1822-1829.